Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial
Article first published online: 12 APR 2011
© 2011 Blackwell Publishing Ltd
Journal of Veterinary Pharmacology and Therapeutics
Volume 35, Issue 2, pages 175–183, April 2012
How to Cite
REYMOND, N., SPERANZA, C., GRUET, P., SEEWALD, W. and KING, J. N. (2012), Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial. Journal of Veterinary Pharmacology and Therapeutics, 35: 175–183. doi: 10.1111/j.1365-2885.2011.01297.x
- Issue published online: 5 MAR 2012
- Article first published online: 12 APR 2011
- (Paper received 23 November 2010; accepted for publication 7 March 2011)
Reymond, N., Speranza, C., Gruet, P., Seewald, W., King, J. N. Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial. J. vet. Pharmacol. Therap. 35, 175–183.
Robenacoxib is a member of the coxib class of nonsteroidal anti-inflammatory drugs (NSAID), with high selectivity for the cyclooxygenase (COX)-2 isoform of COX. In this study, the efficacy and tolerability of robenacoxib were compared with those of carprofen in canine osteoarthritis in a multi-centre, prospective, randomized, blinded, positive-controlled noninferiority clinical trial. Both drugs were administered orally once daily at recommended dosages: robenacoxib at 1–2 mg/kg (n = 125 dogs) and racemic carprofen at 2–4 mg/kg (n = 63 dogs) for a total of 12 weeks. The efficacy of the test compounds was assessed by veterinary investigators and owners using numerical rating scales at baseline and days 7, 14, 28, 56 and 84. In both groups, all scores were significantly (P < 0.0001) improved compared with baseline at all time points (days 7–84). Robenacoxib had noninferior efficacy to carprofen for the primary endpoint, the global functional disability, both for all dogs and for the subgroup of dogs in which robenacoxib was not administered during meals. Noninferiority was also demonstrated for three of six veterinary investigator secondary endpoints and four of six owner efficacy endpoints. For haematology and clinical chemistry variables, there were some significant differences from baseline levels but no differences between groups. There were no differences between groups in the frequencies of adverse events, which were reported in 46% dogs with robenacoxib and 52% with carprofen (P = 0.44), which were most frequently mild events affecting the gastrointestinal tract. In conclusion, noninferior efficacy and tolerability of robenacoxib compared with carprofen was demonstrated in dogs with osteoarthritis.